期刊文献+

阿伐那非中间体N-1的合成及其相关杂质研究 被引量:3

Synthesis of Avanafil Intermediate N-1 and Its Related Impurities
下载PDF
导出
摘要 为加强对阿伐那非原料药的质量控制,研究了阿伐那非中间体N-1的合成及其工艺杂质A、B和C引入的原因,并合成了阿伐那非中间体N-1杂质A、B和C。以4-氯-2-甲硫基嘧啶-5-羧酸乙酯(1)为起始原料,经过取代和氧化等反应得到阿伐那非中间体N-1,氧化物继续与3-氯-4-甲氧基苄胺(2)反应得到杂质B,氧化物在碱性条件下水解得到杂质C,4-氯-2-甲硫基嘧啶-5-羧酸乙酯(1)与4-甲氧基苄胺经过取代和氧化等反应得到杂质A,目标化合物的结构经过NMR与MS确证,纯度达97.5%以上(HPLC),可作为阿伐那非中间体N-1质量控制的杂质对照品。 In order to strengthen the quality control of avanafil API,study on synthesis of avanafil intermediate N-1 and the reason of its A,B and C impurities that are introduced,and the synthesis of intermediate N-1 avanafil impurities A,B and C.Using ethyl 4-chloro-2-methylthiopyrimidine-5-carboxylate(1)as the starting material,avanafil intermediate N-1 was obtained through substitution,oxidation reaction,the oxide continued to react with 3-chloro-4-methoxybenzylamine(2)to obtain impurity B,the oxide is hydrolyzed under alkaline conditions to obtain impurity C,Ethyl 4-chloro-2-methylthiopyrimidine-5-carboxylate(1)reacted with 4-methoxybenzylamine to obtain impurity A,the structure of the target compound by NMR and MS spectra,HPLC detection of purity was more than 99.5%,can be used as intermediate avanafil N-1 quality control of impurity reference.
作者 胡华南 吴秀荣 黄华南 彭游 严平 叶友余 HU Hua-nan;WU Xiu-rong;HUANG Hua-nan;PENG You;YAN Ping;YE You-yu(College of Chemistry and Chemical Engineering,Jiujiang University,Jiujiang 332005,China;Jiujiang Shanshui Technology Co.,Ltd.,Jiujiang 332700,China)
出处 《精细化工中间体》 CAS 2021年第5期31-34,共4页 Fine Chemical Intermediates
基金 江西省教育厅科技项目(GJJ170962) 国家自然科学基金项目(81660541)。
关键词 阿伐那非 PDE5抑制剂 杂质 Avanafil PDE5 inhibitors impurity
  • 相关文献

参考文献5

二级参考文献53

  • 1Wei ZHANG Ni SONG Zhong Zhen LI Ying Xia LI.Synthesis of Obyanamide, a Marine Cytotoxic Cyclic Depsipeptide[J].Chinese Chemical Letters,2006,17(3):285-288. 被引量:3
  • 2US FDA. FDA approves Stendra for erectile dysfunction[ EB/ OL ]. [ 2012 - 04 - 27 ]. http ://www. fda. gov/NewsEven- ts/Newsroom/PressAnnouneements/ucm302140, htm.
  • 3YAMADA K,MATSUKI K, OMORI K,et al. Aromatic ni- trogen-containing 6-membered cyclic compounds : US, 6797709 [ P ]. 2004 - 09 - 28.
  • 4LUE T F, GIULIANO F, MONTORSI F, et al. Summary of the recommendations on sexual dysfunctions in men [ J ]. J Sex Med,2004,1 (1) : 6 -23.
  • 5DEAN R C, LUE T F. Physiology of penile erection and pathophysiology of erectile dysfunction [ J ]. Urol Clin North Am,2005,32(4) : 379 -395.
  • 6Selvin E, Bumett A L, Platz E A. Prevalence and risk factors for erectile dysfunction in the US [ J ]. Am J Med , 2007,120(2) : 151 - 157.
  • 7Hatziehristou D, Rosen R C, Broderick G, et al. Clinical evaluation and management strategy for sexual dysfunction in men and women [J]. J Sex Mcd ,2004, 1(1) : 49 -57.
  • 8Khorombi, T E. A chemical and pharmacological investigation of three South African plants [ D ]. Pietermarltzburg: University of KwaZulu Natal, 2006.
  • 9Jeremy, J Y,Ballard,et al. [J] British J. Urology 1997, 79: 958 - 963.
  • 10W B Smith II, I R McCaslin, A Gokce, ct al. PDES inhibitors: considerations for preference and long- term adherence [J]. Int J in Pratt ,2013,67(8) : 768 -780.

共引文献15

同被引文献11

引证文献3

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部